Levetiracetam in focal epilepsy and hepatic porphyria: a case report.
We report a patient with focal epilepsy and latent hereditary coproporphyria who had exacerbation of clinical symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without exacerbation of clinically latent porphyria.
Paul
Friedemann
F
Meencke
Heinz-Joachim
HJ
D000208:Acute Disease; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use*; D015897:Comorbidity; D004828:Epilepsies, Partial / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D010889:Piracetam / Q000031:analogs & derivatives / Q000627:therapeutic use*; D017094:Porphyrias, Hepatic / Q000139:chemically induced* / Q000188:drug therapy* / Q000453:epidemiology; D011324:Primidone / Q000009:adverse effects / Q000627:therapeutic use; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000927:Anticonvulsants; D011324:Primidone; D000077287:Levetiracetam; D014635:Valproic Acid; D010889:Piracetam